No Data
No Data
Unveiling 6 Analyst Insights On Capricor Therapeutics
Analysts' ratings for Capricor Therapeutics (NASDAQ:CAPR) over the last quarter vary from bullish to bearish, as provided by 6 analysts.The table below provides a concise overview of recent ratings by
Capricor Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 726.45% HC Wainwright & Co. $40 → $40 Reiterates Buy → Buy 05/17/2024 189.26% Oppenheimer → $14
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Joseph Pantginis maintains $Capricor Therapeutics(CAPR.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate
Capricor Therapeutics' CAP-1002 Shows Promise in DMD Treatment: Buy Rating Affirmed Following Positive Clinical Trials
Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today
Capricor Therapeutics (CAPR) Gets a Buy From Oppenheimer